Literature DB >> 31060987

Importance of the initial response to GPi deep brain stimulation in dystonia: A nine year quality of life study.

Takashi Tsuboi1, Zakia Jabarkheel1, Kelly D Foote2, Michael S Okun1, Aparna Wagle Shukla3.   

Abstract

BACKGROUND: Long-term efficacy of deep brain stimulation (DBS) on health-related quality-of-life (HRQoL) for isolated dystonia is not well established. This study aims to determine the long-term impact of DBS on HRQoL outcomes and identify clinical predictors.
METHODS: We retrospectively investigated 16 inherited or idiopathic isolated dystonia patients treated with bilateral globus pallidus internus DBS who were followed beyond 9 years at our center. The cohort consisted of 9 males, 7 females; 10 generalized, 6 segmental; mean (range) age at implantation, 37.0 (8-67) years; mean follow-up duration after implantation, 10.9 (9-13) years. We employed the Unified Dystonia Rating Scale for motor and Short Form Health Survey for HRQoL assessments to monitor the change longitudinally. We analyzed the changes in motor and HRQoL at 1-2 years (short-term) and ≥9 years (long-term) follow-up as compared to baseline with a Wilcoxon signed-rank test. We assessed the factors that predicted motor and HRQoL improvement with univariate regression analyses.
RESULTS: Motor (41.6%; p = 0.004) and HRQoL (total score, p = 0.039) improvements remained significant at long-term follow-up and, in the regression analysis, change in HRQoL outcomes correlated significantly with change in motor outcomes (R2 = 0.384, p = 0.010). Additionally, short-term motor and HRQoL improvements predicted the long-term motor (R2 = 0.384, p = 0.010) and HRQoL (total score, R2 = 0.594, p < 0.001) outcomes, respectively.
CONCLUSION: Motor and HRQoL improvements with DBS in isolated dystonia remain sustained for nearly a decade and may largely be predictable by the short-term response to DBS.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31060987     DOI: 10.1016/j.parkreldis.2019.04.024

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

1.  A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia.

Authors:  Takashi Tsuboi; Joshua K Wong; Leonardo Almeida; Christopher W Hess; Aparna Wagle Shukla; Kelly D Foote; Michael S Okun; Adolfo Ramirez-Zamora
Journal:  J Neurol       Date:  2020-01-14       Impact factor: 4.849

2.  Functional and Structural Connectivity Patterns Associated with Clinical Outcomes in Deep Brain Stimulation of the Globus Pallidus Internus for Generalized Dystonia.

Authors:  L Okromelidze; T Tsuboi; R S Eisinger; M R Burns; M Charbel; M Rana; S S Grewal; C-Q Lu; L Almeida; K D Foote; M S Okun; E H Middlebrooks
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-13       Impact factor: 3.825

3.  Quality of life outcomes after deep brain stimulation in dystonia: A systematic review.

Authors:  Takashi Tsuboi; Joshua K Wong; Michael S Okun; Adolfo Ramirez-Zamora
Journal:  Parkinsonism Relat Disord       Date:  2019-11-18       Impact factor: 4.402

4.  Basal ganglia engagement during REM sleep movements in Parkinson's disease.

Authors:  Ajay K Verma; Sergio Francisco Acosta Lenis; Joshua E Aman; David Escobar Sanabria; Jing Wang; Amy Pearson; Meghan Hill; Remi Patriat; Lauren E Schrock; Scott E Cooper; Michael C Park; Noam Harel; Michael J Howell; Colum D MacKinnon; Jerrold L Vitek; Luke A Johnson
Journal:  NPJ Parkinsons Dis       Date:  2022-09-12

5.  Pediatric Deep Brain Stimulation for Dystonia: Current State and Ethical Considerations.

Authors:  Katrina A MuÑoz; Jennifer Blumenthal-Barby; Eric A Storch; Laura Torgerson; Gabriel LÁzaro-MuÑoz
Journal:  Camb Q Healthc Ethics       Date:  2020-10       Impact factor: 1.566

6.  Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years.

Authors:  P Krause; S Völzmann; S Ewert; A Kupsch; G H Schneider; Andrea A Kühn
Journal:  J Neurol       Date:  2020-02-13       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.